[go: up one dir, main page]

AU1095695A - Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction - Google Patents

Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction

Info

Publication number
AU1095695A
AU1095695A AU10956/95A AU1095695A AU1095695A AU 1095695 A AU1095695 A AU 1095695A AU 10956/95 A AU10956/95 A AU 10956/95A AU 1095695 A AU1095695 A AU 1095695A AU 1095695 A AU1095695 A AU 1095695A
Authority
AU
Australia
Prior art keywords
hmg
normalization
vascular endothelial
coa reductase
reductase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10956/95A
Inventor
R. Wayne Alexander
Stephen J Boccuzzi
Mark A Creager
Peter Ganz
Laurence J. Hirsch III
Yale B Mitchel
Diane J Plotkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Emory University
Merck and Co Inc
Original Assignee
Brigham and Womens Hospital Inc
Emory University
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Emory University, Merck and Co Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU1095695A publication Critical patent/AU1095695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10956/95A 1993-11-09 1994-11-09 Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction Abandoned AU1095695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925293A 1993-11-09 1993-11-09
US149252 1993-11-09
PCT/US1994/013068 WO1995013063A1 (en) 1993-11-09 1994-11-09 HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
AU1095695A true AU1095695A (en) 1995-05-29

Family

ID=22529424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10956/95A Abandoned AU1095695A (en) 1993-11-09 1994-11-09 Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction

Country Status (2)

Country Link
AU (1) AU1095695A (en)
WO (1) WO1995013063A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
IL123902A (en) * 1995-11-02 2003-01-12 Warner Lambert Co PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
EP0807435A3 (en) * 1996-05-17 1999-02-24 Sertürner Arzneimittel GmbH Indirect HMG-CoA-reductase inhibitor
FR2751540B1 (en) 1996-07-26 1998-10-16 Sanofi Sa ANTITHROMBOTIC PHARMACEUTICAL COMPOSITION
US6251852B1 (en) 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
EP1117392B1 (en) * 1998-09-30 2004-02-25 Warner-Lambert Company Llc Method for preventing or delaying catheter-based revascularization
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
RU2276997C2 (en) 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Renin-angiotensin system inhibitors application for preventing cardiovascular disease manifestations
WO2004096276A1 (en) 2003-04-28 2004-11-11 Sankyo Company, Limited Sugar intake-ability enhancer
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
LV14963B (en) 2013-06-28 2015-10-20 Tetra, Sia Corrector of endothelial dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
CA2040865C (en) * 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug

Also Published As

Publication number Publication date
WO1995013063A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
AU2058992A (en) HMG-COA reductase inhibitors
AU2209599A (en) Methods and systems for the inhibition of vascular hyperplasia
AU6157396A (en) Bis-arylsulfonylaminobenzamide derivatives and the use there of as factor xa inhibitors
AU1095695A (en) Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
AU5781100A (en) Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
AU4482897A (en) Methods and compositions for the detection of Candida spp.
AU5439998A (en) Vascular endothelial growth factor
AU6527090A (en) Substituted cyclohexene derivatives as hmg-coa reductase inhibitors
AU2421797A (en) Spirocycle integrin inhibitors
AU6253996A (en) Inhibition of exoprotein in absorbent article
AU7761398A (en) Hmg-coa reductase inhibitor preparation process
AU6090594A (en) Angiotensin ii inhibitors
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
CY2216B1 (en) Enzymatic hydroxylation process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
EP0323866A3 (en) Novel hmg-coa reductase inhibitors
AU2175088A (en) Novel hmg-coa reductase inhibitors
AU645287B2 (en) Quinoline and pyridine anchors for HMG-CoA reductase inhibitors
AU6274694A (en) Methods and compositions for the inhibition of complement activation
AU1811397A (en) Imidazole derivatives and vascular wall thickening inhibitor
EP0415488A3 (en) 7-substituted hmg-coa reductase inhibitors
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU2202792A (en) Specific inhibition of dihydrofolate reductase and compounds therefor
AU2001243248A1 (en) Method for the prevention or reduction of vascular access dysfunction
AU6496300A (en) Systems and methods for the completion of transactions
AU4578197A (en) Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin